Editas Medicine reports $270M cash, new in vivo preclinical data, and 2025-2027 strategic priorities

Editas Medicine, Inc.

Preliminary cash, equivalents, marketable securities ~$270M as of Dec 31, 2024; operational runway into Q2 2027.
Achieved in vivo editing of hematopoietic stem cells in non-human primates using proprietary tLNPs; further optimization underway.
Achieved proof of concept for AsCas12a LNP delivery in liver cells in non-human primates; also demonstrated upregulation in mice.
Anticipates declaring two in vivo development candidates by mid-2025: HSC for sickle cell/beta thalassemia and liver for undisclosed indication.
Strategic priorities through 2027: submit at least one IND/CTA by mid-2026, start human trials H2 2026, initiate late-stage trial H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.